Maximilian Merz

Dr. Maximilian Merz is a hematologist-oncologist and Associate Attending Physician at Memorial Sloan Kettering Cancer Center in New York specializing in multiple myeloma and focused on the optimization of CAR T therapies. Following his medical training in Heidelberg, Germany, and a research fellowship at Roswell Park Cancer Center in Buffalo, New York, he held a clinical leadership role as head of the Early Clinical Trial Unit in Leipzig, Germany. His translational research uses advanced bioinformatic analyses of longitudinal and spatially-resolved single-cell multi-omics to understand treatment response, resistance, and side effects. Dr. Merz has published as first and senior author in Nature Medicine, Nature Cancer, Cancer Cell, JCO, and Lancet Hematology, serves on the editorial board of Leukemia, and has received awards from ASH, ASCO, and EHA. His goal is to develop curative immunotherapies for multiple myeloma and to make long-term remission achievable for most patients by 2030.